Page 6,948«..1020..6,9476,9486,9496,950..6,9606,970..»

How Genes Organize the Surface of the Brain

Posted: Published on March 29th, 2012

Newswise The first atlas of the surface of the human brain based upon genetic information has been produced by a national team of scientists, led by researchers at the University of California, San Diego School of Medicine and the VA San Diego Healthcare System. The work is published in the March 30 issue of the journal Science. The atlas reveals that the cerebral cortex the sheet of neural tissue enveloping the brain is roughly divided into genetic divisions that differ from other brain maps based on physiology or function. The genetic atlas provides scientists with a new tool for studying and explaining how the brain works, particularly the involvement of genes. Genetics are important to understanding all kinds of biological phenomena, said William S. Kremen, PhD, professor of psychiatry at the UC San Diego School of Medicine and co-senior author with Anders M. Dale, PhD, professor of radiology, neurosciences, and psychiatry, also at the UC San Diego School of Medicine. According to Chi-Hua Chen, PhD, first author and a postdoctoral fellow in the UC San Diego Department of Psychiatry, If we can understand the genetic underpinnings of the brain, we can get a better idea of how it develops and … Continue reading

Comments Off on How Genes Organize the Surface of the Brain

Researchers identify genetic basis of tropical foot and leg lymphedema

Posted: Published on March 29th, 2012

Public release date: 28-Mar-2012 [ | E-mail | Share ] Contact: Raymond MacDougall macdougallr@mail.nih.gov 301-402-0911 NIH/National Human Genome Research Institute Farmers in the highlands of southern Ethiopia scratch out a subsistence living from the region's volcanic red clay. The soil supports the farms, but fine-grained, volcanic rock particles in the dirt threaten the farmers and their families. Continual exposure of bare feet to the volcanic soil causes 1 in 20 people to develop a painful inflammation of the lower extremities that, over time, leads to foot disfigurement. Doctors call it podoconiosis. The locals call it mossy foot. And those affected suffer social stigma as well as debilitating discomfort. Now, researchers think they know why some 4 million people in at least 10 countries worldwide develop this incapacitating condition. One-fifth carry genetic variants that cause their immune system to react to the volcanic dust. This disease-producing response, triggered by exposure from the lack of shoes, provides a dramatic example of the interaction between genes and the environment. Writing in the March 29, 2012 New England Journal of Medicine, an international team that includes researchers from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, describes the … Continue reading

Comments Off on Researchers identify genetic basis of tropical foot and leg lymphedema

New Layer of Genetic Information Discovered

Posted: Published on March 29th, 2012

Newswise A hidden and never before recognized layer of information in the genetic code has been uncovered by a team of scientists at the University of California, San Francisco (UCSF) thanks to a technique developed at UCSF called ribosome profiling, which enables the measurement of gene activity inside living cells including the speed with which proteins are made. By measuring the rate of protein production in bacteria, the team discovered that slight genetic alterations could have a dramatic effect. This was true even for seemingly insignificant genetic changes known as silent mutations, which swap out a single DNA letter without changing the ultimate gene product. To their surprise, the scientists found these changes can slow the protein production process to one-tenth of its normal speed or less. As described today in the journal Nature, the speed change is caused by information contained in what are known as redundant codons small pieces of DNA that form part of the genetic code. They were called redundant because they were previously thought to contain duplicative rather than unique instructions. This new discovery challenges half a century of fundamental assumptions in biology. It may also help speed up the industrial production of proteins, which … Continue reading

Comments Off on New Layer of Genetic Information Discovered

New layer of genetic information helps determine how fast proteins are produced

Posted: Published on March 29th, 2012

ScienceDaily (Mar. 28, 2012) A hidden and never before recognized layer of information in the genetic code has been uncovered by a team of scientists at the University of California, San Francisco (UCSF) thanks to a technique developed at UCSF called ribosome profiling, which enables the measurement of gene activity inside living cells -- including the speed with which proteins are made. By measuring the rate of protein production in bacteria, the team discovered that slight genetic alterations could have a dramatic effect. This was true even for seemingly insignificant genetic changes known as "silent mutations," which swap out a single DNA letter without changing the ultimate gene product. To their surprise, the scientists found these changes can slow the protein production process to one-tenth of its normal speed or less. As described March 28 in the journal Nature, the speed change is caused by information contained in what are known as redundant codons -- small pieces of DNA that form part of the genetic code. They were called "redundant" because they were previously thought to contain duplicative rather than unique instructions. This new discovery challenges half a century of fundamental assumptions in biology. It may also help speed up … Continue reading

Comments Off on New layer of genetic information helps determine how fast proteins are produced

Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored

Posted: Published on March 29th, 2012

Public release date: 29-Mar-2012 [ | E-mail | Share ] Contact: Elizabeth Lynch elynch@marchofdimes.com 914-997-4286 March of Dimes Foundation CHARLOTTE, NC -- A long-time clinician and researcher on Marfan syndrome who helped identify the syndrome's genetic cause and a potential treatment will be honored by the March of Dimes. Harry (Hal) Dietz, MD, the Victor A. McKusick Professor of Institute of Genetic Medicine and Professor of Pediatrics, at Johns Hopkins University School of Medicine and Howard Hughes Medical Institute Investigator, will receive the March of Dimes/Colonel Harland Sanders Award for Lifetime Achievement in the field of genetic sciences. Dr. Joe Leigh Simpson, senior vice president for Research and Global Programs of the March of Dimes, will present the award to Dr. Dietz today during the annual Clinical Genetics Meeting of the American College of Medical Genetics at Charlotte Convention Center. Marfan syndrome is an inherited connective tissue disorder that affects about 1 in 5,000 people. The syndrome is caused by a genetic defect which causes overgrowth of the body's long bones and affects the tissue that strengthens the body's structures, including the skeletal system, cardiovascular system, eyes, and skin. Those who have the syndrome tend to be tall with arms … Continue reading

Comments Off on Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored

NeoStem Announces Pricing of Public Offering for $6,000,000 in Gross Proceeds

Posted: Published on March 29th, 2012

NEW YORK, March 29, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or "the Company"), a leader in the cell therapy industry, announced today the pricing of an underwritten public offering of 15,000,000 units at $0.40 per unit. Each unit consists of one share of common stock and a warrant to purchase one share of common stock with a per share exercise price of $0.51. Maxim Group LLC acted as sole bookrunner. The Company expects to receive $6,000,000 in gross proceeds, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. These funds will be used for working capital purposes, including research and development of cell therapeutic product candidates, expansion of business units, strategic transactions and other general corporate purposes. The Company has granted the underwriters a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments. The financing is expected to close on or about April 3, 2012, subject to the satisfaction of customary closing conditions. This offering is being made by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from the Securities and Exchange … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on NeoStem Announces Pricing of Public Offering for $6,000,000 in Gross Proceeds

Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Posted: Published on March 29th, 2012

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at: http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports. Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Stem cell therapy for the repair of myocardium in heart failure patients – Video

Posted: Published on March 29th, 2012

28-03-2012 10:17 Dr Joshua Hare is Professor of Medicine and Director of the Interdisciplinary Stem Cell Institute at the University of Miami. The interview was conducted on 25 March 2012 at the American College of Cardiology's (ACC's) 61st Annual Scientific Session & Expo in Chicago. See more ACC.12 Coverage: http://www.getinsidehealth.com More here: Stem cell therapy for the repair of myocardium in heart failure patients - Video … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Stem cell therapy for the repair of myocardium in heart failure patients – Video

NeoStem Announces Proposed Public Offering of Common Stock and Warrants

Posted: Published on March 29th, 2012

NEW YORK, March 28, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or "the Company"), a leader in the cell therapy industry, today announced that it intends to offer and sell shares of its common stock and warrants in an underwritten public offering. All of the shares and warrants in the offering will be sold by NeoStem. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The securities will be issued pursuant to a prospectus supplement filed as part of an effective registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC). Maxim Group LLC is acting as book-runner of the offering. A shelf registration statement relating to the securities was filed with the SEC, which became effective on June 13, 2011. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Maxim Group LLC, 405 … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on NeoStem Announces Proposed Public Offering of Common Stock and Warrants

Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Posted: Published on March 29th, 2012

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at: http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports. Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the … Continue reading

Comments Off on Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation

Page 6,948«..1020..6,9476,9486,9496,950..6,9606,970..»